普瑞巴林市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球普瑞巴林市場價值為 18 億美元，預計到 2034 年將以 5.1% 的複合年成長率成長，達到 30 億美元。這種持續上升的趨勢反映了對慢性神經系統疾病（包括神經性疼痛、癲癇和廣泛性焦慮症 (GAD)）的有效治療的需求不斷成長。普瑞巴林因其抗驚厥和鎮痛的雙重作用，已成為全球製藥領域的基石。醫療保健專業人士擴大將其作為鴉片類藥物的更安全替代品，特別是在長期疼痛管理中。它在醫院、零售藥局和線上平台的日益普及證明了其治療的可靠性。無論是在已開發地區還是新興地區，不斷擴大的患者群體、不斷提高的健康意識以及醫療保健服務的改善都在加速市場滲透。人們對慢性疼痛狀況的認知不斷提高，加上全球向非鴉片類藥物治療方案的轉變，繼續為全球製造商和供應商創造有利可圖的成長機會。此外，有利的監管框架和醫療保健領域不斷成長的投資正在推動製藥公司加強在該領域的影響力，推動創新和商業化策略。

普瑞巴林市場主要分為兩種劑型：錠劑、膠囊劑和口服液。藥片和膠囊仍然是患者和醫療保健提供者的首選，主要是因為它們使用方便且劑量一致。預計該領域的複合年成長率為 5.1%，到 2034 年將達到 23 億美元。固體劑型帶來的便利性對於管理慢性病的患者尤其重要，因為與液體製劑相比，藥片和膠囊更容易儲存、運輸和服用。此外，製藥公司不斷擴大其產品線，提供不同劑量的產品，從而實現更個人化的治療方案並提高患者的依從性。

從應用方面來看，普瑞巴林市場分為癲癇、神經性疼痛、廣泛性焦慮症和其他用途。其中，神經性疼痛領域預計將以 5.2% 的複合年成長率實現最快成長，到 2034 年將達到 16 億美元。糖尿病、癌症和老化相關神經損傷發病率的上升正在推動對有效神經性疼痛療法的需求。醫療保健提供者優先考慮早期診斷和及時干預，而患者則擴大尋求傳統疼痛緩解方法的永續替代方案。因此，普瑞巴林作為神經病學的一線治療選擇繼續受到青睞。

2024 年美國普瑞巴林市場價值為 7.54 億美元，預計將維持強勁成長動能。慢性神經病變的激增，加上人們對鴉片類藥物依賴相關風險的認知提高，推動了這一趨勢。普瑞巴林作為非鴉片類止痛藥的定位使其成為醫生和患者的首選，特別是在治療糖尿病神經病變和帶狀皰疹後神經痛等疾病方面。

影響全球普瑞巴林市場格局的知名企業包括 Zydus Lifesciences、Cipla、Teva Pharmaceutical Industries、Aurobindo Pharma、Amneal Pharmaceuticals、Apotex、Dr. Reddy's Laboratories、Torrent Pharmaceuticals、輝瑞、Hikma Pharmaceuticals、Sunaborceuticals、Sunaborceuticals、諾華、Hikma Pharmaceuticals、Sunaborceuticals、Luaborceuticals、AlFator、AlFators、Luaborceuticals。這些公司不斷投資研發以增強普瑞巴林的配方。策略合作、收購和擴大生產能力正在幫助產業領導者滿足不斷成長的全球需求，同時保持競爭力。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 神經性疼痛和癲癇的盛行率不斷上升
    • 老年人口不斷增加
    • 擴大新適應症的批准
    • 通用版本的可用性不斷提高
  • 產業陷阱與挑戰
    • 嚴格的監管要求
    • 濫用和成癮的風險
• 成長潛力分析
• 監管格局
• 技術格局
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按配方，2021 - 2034 年

• 主要趨勢
• 片劑和膠囊
• 口服溶液

第6章：市場估計與預測：按應用，2021 - 2034 年

• 主要趨勢
• 神經性疼痛
• 癲癇
• 廣泛性焦慮症
• 其他應用

第7章：市場估計與預測：按配銷通路，2021 - 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 電子商務

第8章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Alkem Laboratories
• Amneal Pharmaceuticals
• Apotex
• Aurobindo Pharma
• Cipla
• Dr. Reddy's Laboratories
• Hikma Pharmaceuticals
• Lupin
• Novartis
• Pfizer
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals
• Viatris
• Zydus Lifesciences

The Global Pregabalin Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 5.1% to reach USD 3 billion by 2034. This consistent upward trajectory reflects the rising demand for effective treatments targeting chronic neurological conditions, including neuropathic pain, epilepsy, and generalized anxiety disorder (GAD). Pregabalin has become a cornerstone in the global pharmaceutical landscape due to its dual action as an anticonvulsant and analgesic. Healthcare professionals are increasingly prescribing it as a safer alternative to opioids, especially in long-term pain management. Its growing acceptance across hospitals, retail pharmacies, and online platforms is a testament to its therapeutic reliability. In both developed and emerging regions, an expanding patient base, rising health awareness, and improvements in healthcare access are accelerating market penetration. Increased awareness around chronic pain conditions, combined with a global shift toward non-opioid treatment options, continues to create lucrative growth opportunities for manufacturers and suppliers worldwide. Additionally, favorable regulatory frameworks and growing investments in the healthcare sector are pushing pharmaceutical companies to strengthen their presence in this space, fueling innovation and commercialization strategies.

The pregabalin market is segmented into two primary formulations: tablets and capsules and oral solutions. Tablets and capsules remain the preferred choice among patients and healthcare providers, primarily because of their ease of use and consistent dosing. This segment is projected to grow at a CAGR of 5.1%, reaching USD 2.3 billion by 2034. The convenience offered by solid dosage forms is especially important for patients managing chronic conditions, as tablets and capsules are easier to store, transport, and consume compared to liquid formulations. Moreover, pharmaceutical companies continue to expand their product lines with varied dosage strengths, enabling more personalized treatment regimens and enhancing patient adherence.

In terms of application, the pregabalin market is categorized into epilepsy, neuropathic pain, generalized anxiety disorder, and other uses. Among these, the neuropathic pain segment is anticipated to record the fastest growth at a CAGR of 5.2%, reaching USD 1.6 billion by 2034. Rising incidences of diabetes, cancer, and aging-related nerve damage are fueling the demand for effective neuropathic pain therapies. Healthcare providers are prioritizing early diagnosis and timely intervention, while patients increasingly seek sustainable alternatives to traditional pain relief methods. As a result, pregabalin continues to gain momentum as a first-line treatment option in neurology.

The U.S. Pregabalin Market was valued at USD 754 million in 2024 and is expected to maintain strong growth momentum. A surge in chronic neuropathic disorders, coupled with heightened awareness about the risks associated with opioid dependency, is driving this trend. Pregabalin's positioning as a non-opioid pain reliever has made it a preferred choice among physicians and patients alike, particularly in managing conditions like diabetic neuropathy and post-herpetic neuralgia.

Prominent players shaping the global pregabalin market landscape include Zydus Lifesciences, Cipla, Teva Pharmaceutical Industries, Aurobindo Pharma, Amneal Pharmaceuticals, Apotex, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Sun Pharmaceutical Industries, Novartis, Alkem Laboratories, Lupin, and Viatris. These companies are consistently investing in research and development to enhance pregabalin formulations. Strategic collaborations, acquisitions, and expanded production capacities are helping industry leaders meet rising global demand while staying competitive.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of neuropathic pain and epilepsy
    • 3.2.1.2 Growing geriatric population
    • 3.2.1.3 Expanding approval for new indications
    • 3.2.1.4 Increasing availability of generic versions
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Risk of misuse and addiction
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Formulation, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Tablets and capsules
• 5.3 Oral solution

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Neuropathic pain
• 6.3 Epilepsy
• 6.4 Generalized anxiety disorder
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Alkem Laboratories
• 9.2 Amneal Pharmaceuticals
• 9.3 Apotex
• 9.4 Aurobindo Pharma
• 9.5 Cipla
• 9.6 Dr. Reddy’s Laboratories
• 9.7 Hikma Pharmaceuticals
• 9.8 Lupin
• 9.9 Novartis
• 9.10 Pfizer
• 9.11 Sun Pharmaceutical Industries
• 9.12 Teva Pharmaceutical Industries
• 9.13 Torrent Pharmaceuticals
• 9.14 Viatris
• 9.15 Zydus Lifesciences